MX2010005225A - Phenylpyrazole derivatives. - Google Patents

Phenylpyrazole derivatives.

Info

Publication number
MX2010005225A
MX2010005225A MX2010005225A MX2010005225A MX2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A
Authority
MX
Mexico
Prior art keywords
alkyl
disorder
halogeno
general formula
sleep
Prior art date
Application number
MX2010005225A
Other languages
Spanish (es)
Inventor
Shigeyuki Chaki
Dai Nozawa
Tomoko Tamita
Toshio Nakamura
Makoto Tatsuzuki
Seiji Masuda
Hiroshi Ohta
Shuhei Kashiwa
Aya Fujino
Toshiharu Shimazaki
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MX2010005225A publication Critical patent/MX2010005225A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides preventive or therapeutic drugs for dementia, Alzheimer disease, attention deficit/hyperactivity disorder, schizophrenia, eating disorder, obesity, diabetes, hyperlipemia, sleep disorder, narcolepsy, sleep-apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis, and other diseases. Phenylpyrazole derivatives represented by the general formula (1) or pharmaceutically acceptable salts thereof, wherein R1 and R2 may be the same or different and are each C1-6 alkyl or C3-8 cycloalkyl, or R1 and R2 together with the nitrogen atom adjacent to both may form a 4- to 7-membered saturated heterocycle (which may be substituted with halogeno and C1-6 alkyl); n is an integer of 0 to 2; T is hydrogen, halogeno, or C1-6 alkyl; and R is a group represented by the general formula (I) or the like.
MX2010005225A 2007-11-13 2008-11-13 Phenylpyrazole derivatives. MX2010005225A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007294040 2007-11-13
JP2008153736 2008-06-12
PCT/JP2008/070712 WO2009063953A1 (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives

Publications (1)

Publication Number Publication Date
MX2010005225A true MX2010005225A (en) 2010-05-27

Family

ID=40638800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005225A MX2010005225A (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives.

Country Status (24)

Country Link
US (3) US7888354B2 (en)
EP (1) EP2221298B1 (en)
JP (2) JP4543344B2 (en)
KR (1) KR101571176B1 (en)
CN (1) CN101855211B (en)
AU (1) AU2008321823B2 (en)
BR (1) BRPI0820432B8 (en)
CA (1) CA2705502C (en)
CY (1) CY1114877T1 (en)
DK (1) DK2221298T3 (en)
ES (1) ES2436146T3 (en)
HK (1) HK1145834A1 (en)
HR (1) HRP20131060T1 (en)
IL (2) IL205509A (en)
MX (1) MX2010005225A (en)
MY (1) MY173546A (en)
NZ (1) NZ585661A (en)
PL (1) PL2221298T3 (en)
PT (1) PT2221298E (en)
RS (1) RS53125B (en)
RU (1) RU2480456C2 (en)
SI (1) SI2221298T1 (en)
WO (1) WO2009063953A1 (en)
ZA (1) ZA201003111B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113776A1 (en) * 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
PL2221298T3 (en) * 2007-11-13 2014-05-30 Taisho Pharmaceutical Co Ltd Phenylpyrazole derivatives
JP5740838B2 (en) * 2009-05-12 2015-07-01 大正製薬株式会社 Phenylpyrazole derivatives
WO2013085018A1 (en) 2011-12-08 2013-06-13 大正製薬株式会社 Phenylpyrrole derivative
TW201343636A (en) 2011-12-27 2013-11-01 大正製藥股份有限公司 Phenyltriazole derivative
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
ES2707323T3 (en) * 2012-12-07 2019-04-03 Chemocentryx Inc Diazol lactams
BR112015016323A2 (en) 2013-01-17 2017-07-11 Hoffmann La Roche oxytocin receptor agonists for treatment of cns diseases
CN109310677A (en) 2016-04-07 2019-02-05 凯莫森特里克斯股份有限公司 Tumor load is reduced by the way that CCR1 antagonist and PD-1 inhibitor or PD-L1 antagonist is administered in combination

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JP2004511438A (en) 2000-08-08 2004-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Aryloxypiperidine containing no imidazole
US6316475B1 (en) 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
WO2002074758A2 (en) * 2001-03-16 2002-09-26 Abbott Laboratories Novel amines as histamine-3 receptor ligands and their therapeutic applications
EP1642898B1 (en) 2003-06-27 2013-03-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
WO2005097751A2 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (en) 2004-05-25 2006-08-04 Sanofi Synthelabo TETRAHYDROISOQUINOLYLSULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
SE0401971D0 (en) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
AU2005277518B2 (en) 2004-08-23 2011-08-04 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
CA2584318A1 (en) 2004-10-19 2006-05-04 F. Hoffmann-La Roche Ag Quinoline derivatives
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
CN101111480A (en) 2004-12-01 2008-01-23 万有制药株式会社 Substituted pyridone derivative
EP1833796A1 (en) 2004-12-07 2007-09-19 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
AU2006228690A1 (en) 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
BRPI0608653A2 (en) 2005-04-01 2010-11-30 Lilly Co Eli compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of a compound or salt thereof
DE102005033448A1 (en) * 2005-07-18 2007-01-25 Josef Gail Compressed gas cylinder rotor motor
GB0514812D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0514811D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2641441A1 (en) * 2006-02-09 2007-08-23 Athersys, Inc. Pyrazoles for the treatment of obesity and other cns disorders
US20100113776A1 (en) 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
WO2008125592A1 (en) * 2007-04-12 2008-10-23 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing o-chloromethylphenylglyoxylic esters, improved process for preparing (e)-2-(2-chloromethylphenyl)-2-alkoximinoacetic esters, and novel intermediates for their preparation
PL2221298T3 (en) * 2007-11-13 2014-05-30 Taisho Pharmaceutical Co Ltd Phenylpyrazole derivatives

Also Published As

Publication number Publication date
CA2705502C (en) 2016-01-26
PL2221298T3 (en) 2014-05-30
AU2008321823A1 (en) 2009-05-22
KR20100083795A (en) 2010-07-22
IL205509A (en) 2015-09-24
WO2009063953A1 (en) 2009-05-22
US20110065667A1 (en) 2011-03-17
CN101855211B (en) 2013-06-12
US8183387B2 (en) 2012-05-22
PT2221298E (en) 2013-12-03
BRPI0820432B8 (en) 2021-05-25
SI2221298T1 (en) 2013-12-31
MY173546A (en) 2020-02-04
ZA201003111B (en) 2011-08-31
BRPI0820432A2 (en) 2015-05-26
CY1114877T1 (en) 2016-12-14
KR101571176B1 (en) 2015-11-23
DK2221298T3 (en) 2013-11-18
JP2010143943A (en) 2010-07-01
RU2480456C2 (en) 2013-04-27
IL205509A0 (en) 2010-12-30
HK1145834A1 (en) 2011-05-06
HRP20131060T1 (en) 2013-12-20
US20100267687A1 (en) 2010-10-21
BRPI0820432B1 (en) 2020-01-14
RS53125B (en) 2014-06-30
CA2705502A1 (en) 2009-05-22
EP2221298A4 (en) 2011-09-21
US8193176B2 (en) 2012-06-05
JP4543344B2 (en) 2010-09-15
US20110065668A1 (en) 2011-03-17
AU2008321823B2 (en) 2013-03-07
EP2221298B1 (en) 2013-11-06
EP2221298A1 (en) 2010-08-25
JPWO2009063953A1 (en) 2011-03-31
JP5375639B2 (en) 2013-12-25
US7888354B2 (en) 2011-02-15
NZ585661A (en) 2012-04-27
IL236083A0 (en) 2015-01-29
RU2010123924A (en) 2011-12-20
IL236083A (en) 2016-12-29
ES2436146T3 (en) 2013-12-27
CN101855211A (en) 2010-10-06

Similar Documents

Publication Publication Date Title
MX2010005225A (en) Phenylpyrazole derivatives.
MX2011008336A (en) Dihydroquinolinone derivatives.
NZ617334A (en) Cyclopropyl amine derivatives
EP1845081A4 (en) Amide compound
NO20083114L (en) Polycyclic indazole derivatives which are ERK inhibitors
WO2007085556A3 (en) Use of 4-imidazole derivatives for cns disorders
WO2007057790A3 (en) Substituted bicyclic pyrimidone derivatives
UA98951C2 (en) 2-aminooxazolines and medicament comprising thereof
NO343929B3 (en) 1- [2- (2,4-dimethylphenylsulfanyl-phenyl] -piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5HT1A activity for the treatment of cognitive pain
MX2010008363A (en) Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of gsk3-beta.
ATE478058T3 (en) 3,7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE
BR112012027640A2 (en) compound, pharmaceutical composition, use of a compound, and methods of preparing a pharmaceutical composition, inhibiting the function of 11betahydroxysteroid dehydrogenase type 1 and treating or preventing a disorder
MX2011011489A (en) Isoxazole-pyridine derivatives.
NO20085067L (en) 4,5-diphenyl-pyrimidinyl substituted carboxylic acids, processes for their preparation and use thereof as medicaments
NZ705710A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
NO20091793L (en) 2-pyridinecarboxamide derivative with GK activating effect
NO20083369L (en) Use of substituted 2-imidazole by imidazoline derivatives
MX2010009922A (en) Pyridazinone glucokinase activators.
NO20082112L (en) 3-Amino-2-arylpropylazaindoles and their use
CA2702933A1 (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
MX2011011273A (en) Isoxazole-pyrazole derivatives.
PH12014501293A1 (en) Phenylpyrrole derivative
MX2016016488A (en) Substituted azetidine derivatives as taar ligands.
BRPI0811220A2 (en) THERAPEUTIC COMPOUNDS
AR062295A1 (en) COMPOSITE OF 1H-QUINOLIN-4-ONA, PROCEDURES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
FG Grant or registration